Daytona Street Capital LLC Takes Position in Cencora, Inc. $COR

Daytona Street Capital LLC purchased a new stake in Cencora, Inc. (NYSE:COR) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 40,000 shares of the company’s stock, valued at approximately $13,510,000. Cencora accounts for about 9.0% of Daytona Street Capital LLC’s investment portfolio, making the stock its biggest holding.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Vestcor Inc grew its stake in shares of Cencora by 0.5% in the third quarter. Vestcor Inc now owns 5,196 shares of the company’s stock worth $1,624,000 after acquiring an additional 28 shares during the last quarter. JFS Wealth Advisors LLC grew its stake in shares of Cencora by 30.2% in the fourth quarter. JFS Wealth Advisors LLC now owns 125 shares of the company’s stock worth $42,000 after acquiring an additional 29 shares during the last quarter. Cornerstone Wealth Group LLC grew its stake in shares of Cencora by 1.3% in the third quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company’s stock worth $745,000 after acquiring an additional 30 shares during the last quarter. Security Financial Services INC. grew its stake in shares of Cencora by 2.6% in the third quarter. Security Financial Services INC. now owns 1,325 shares of the company’s stock worth $414,000 after acquiring an additional 33 shares during the last quarter. Finally, Vermillion & White Wealth Management Group LLC grew its stake in shares of Cencora by 31.4% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 138 shares of the company’s stock worth $43,000 after acquiring an additional 33 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Activity at Cencora

In other news, CEO Robert P. Mauch sold 5,096 shares of the business’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the sale, the chief executive officer owned 66,726 shares in the company, valued at approximately $23,669,713.98. The trade was a 7.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.38% of the company’s stock.

Cencora Stock Down 1.3%

COR opened at $320.57 on Tuesday. Cencora, Inc. has a fifty-two week low of $267.40 and a fifty-two week high of $377.54. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51. The firm’s fifty day moving average price is $347.92 and its two-hundred day moving average price is $342.14. The company has a market capitalization of $62.36 billion, a P/E ratio of 38.53, a P/E/G ratio of 1.51 and a beta of 0.72.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The firm had revenue of $85.93 billion for the quarter, compared to the consensus estimate of $86.12 billion. During the same quarter in the previous year, the company earned $3.73 earnings per share. The business’s revenue was up 5.5% compared to the same quarter last year. On average, analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were paid a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date was Friday, February 13th. Cencora’s payout ratio is currently 28.85%.

Analyst Upgrades and Downgrades

COR has been the topic of several research analyst reports. Bank of America lowered their price objective on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research note on Monday, January 5th. Barclays raised their price objective on shares of Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research note on Friday, February 13th. Morgan Stanley set a $380.00 price objective on shares of Cencora in a research note on Tuesday, March 17th. Evercore restated an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Finally, Wells Fargo & Company raised their price objective on shares of Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Twelve investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $403.17.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.